Biomarqueurs tissulaires dans les CBNPC

Tissue biomarkers play a central role in the management of non-small cell lung cancer (NSCLC). The evaluation of predictive biomarkers guides therapeutic decisions by enabling access to targeted therapies or immunotherapy, and forms the foundation of personalized medicine in oncology. The number of biomarkers has increased significantly since the discovery of EGFR gene mutations, due to the development of therapies targeting oncogenic drivers and antibody drug conjugates. These predictive biomarkers include, molecular alterations identified through sequencing (EGFR, BRAF, KRAS, ALK, ROSI, RET, MET, HER2, NTRK, NRG1), and protein biomarkers whose expression is assessed by immunohistochemistry (PD-L1, ALK, ROS1, NTRK, HER2, HER3, MET, TROP2, MTAP, CEACAM5). Testing recommendations in NSCLC are constantly evolving, and it is essential to stay up to date in order to propose the best treatment to each patient.